Robin Jones to Disease Progression
This is a "connection" page, showing publications Robin Jones has written about Disease Progression.
Connection Strength
0.311
-
Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
Score: 0.123
-
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 11; 26(11):e2053-e2060.
Score: 0.039
-
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
Score: 0.039
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
Score: 0.039
-
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Ann Surg Oncol. 2019 Dec; 26(13):4699-4706.
Score: 0.034
-
Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol. 2011 Apr; 50(3):455-61.
Score: 0.018
-
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4.
Score: 0.017